Reardon, D. A. and Dresemann, G. and Taillibert, S. and Campone, M. and van den Bent, M. and Clement, P. and Blomquist, E. and Gordower, L. and Schultz, H. and Raizer, J. and Hau, P. and Easaw, J. and Gil, M. and Tonn, J. and Gijtenbeek, A. and Schlegel, U. and Bergstrom, P. and Green, S. and Weir, A. and Nikolova, Z. (2009) Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. BRITISH JOURNAL OF CANCER, 101 (12). pp. 1995-2004. ISSN 0007-0920,
Full text not available from this repository. (Request a copy)Abstract
BACKGROUND: We evaluated the efficacy of imatinib mesylate in addition to hydroxyurea in patients with recurrent glioblastoma (GBM) who were either on or not on enzyme-inducing anti-epileptic drugs (EIAEDs). METHODS: A total of 231 patients with GBM at first recurrence from 21 institutions in 10 countries were enrolled. All patients received 500 mg of hydroxyurea twice a day. Imatinib was administered at 600 mg per day for patients not on EIAEDs and at 500 mg twice a day if on EIAEDs. The primary end point was radiographic response rate and secondary end points were safety, progression-free survival at 6 months (PFS-6), and overall survival (OS). RESULTS: The radiographic response rate after centralised review was 3.4%. Progression-free survival at 6 months and median OS were 10.6% and 26.0 weeks, respectively. Outcome did not appear to differ based on EIAED status. The most common grade 3 or greater adverse events were fatigue (7%), neutropaenia (7%), and thrombocytopaenia (7%). CONCLUSION: Imatinib in addition to hydroxyurea was well tolerated among patients with recurrent GBM but did not show clinically meaningful anti-tumour activity. British Journal of Cancer (2009) 101, 1995-2004. doi: 10.1038/sj.bjc.6605411 www.bjcancer.com Published online 10 November 2009 (C) 2009 Cancer Research UK
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | GROWTH-FACTOR-RECEPTOR; RECURRENT MALIGNANT GLIOMAS; METASTATIC BRAIN-TUMORS; FREE SURVIVAL; MOUSE MODEL; KINASE INHIBITORS; CLINICAL-TRIALS; PDGF RECEPTORS; IN-VITRO; EXPRESSION; glioblastoma; imatinib mesylate; platelet-derived growth factor; c-KIT |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Neurologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 27 Aug 2020 10:01 |
| Last Modified: | 27 Aug 2020 10:01 |
| URI: | https://pred.uni-regensburg.de/id/eprint/27984 |
Actions (login required)
 |
View Item |
